215 related articles for article (PubMed ID: 22964632)
1. Immunobiology of human mucin 1 in a preclinical ovarian tumor model.
Budiu RA; Elishaev E; Brozick J; Lee M; Edwards RP; Kalinski P; Vlad AM
Oncogene; 2013 Aug; 32(32):3664-75. PubMed ID: 22964632
[TBL] [Abstract][Full Text] [Related]
2. MUC1 positive, Kras and Pten driven mouse gynecologic tumors replicate human tumors and vary in survival and nuclear grade based on anatomical location.
Tirodkar TS; Budiu RA; Elishaev E; Zhang L; Mony JT; Brozick J; Edwards RP; Vlad AM
PLoS One; 2014; 9(7):e102409. PubMed ID: 25078979
[TBL] [Abstract][Full Text] [Related]
3. A conditional mouse model for human MUC1-positive endometriosis shows the presence of anti-MUC1 antibodies and Foxp3+ regulatory T cells.
Budiu RA; Diaconu I; Chrissluis R; Dricu A; Edwards RP; Vlad AM
Dis Model Mech; 2009; 2(11-12):593-603. PubMed ID: 19841240
[TBL] [Abstract][Full Text] [Related]
4. Anti-PD-L1 prolongs survival and triggers T cell but not humoral anti-tumor immune responses in a human MUC1-expressing preclinical ovarian cancer model.
Mony JT; Zhang L; Ma T; Grabosch S; Tirodkar TS; Brozick J; Tseng G; Elishaev E; Edwards RP; Huang X; Vlad AM
Cancer Immunol Immunother; 2015 Sep; 64(9):1095-108. PubMed ID: 25998800
[TBL] [Abstract][Full Text] [Related]
5. Effects of Kras activation and Pten deletion alone or in combination on MUC1 biology and epithelial-to-mesenchymal transition in ovarian cancer.
Zhang L; Ma T; Brozick J; Babalola K; Budiu R; Tseng G; Vlad AM
Oncogene; 2016 Sep; 35(38):5010-20. PubMed ID: 26973247
[TBL] [Abstract][Full Text] [Related]
6. Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival.
Dobrzanski MJ; Rewers-Felkins KA; Quinlin IS; Samad KA; Phillips CA; Robinson W; Dobrzanski DJ; Wright SE
Clin Immunol; 2009 Dec; 133(3):333-52. PubMed ID: 19762283
[TBL] [Abstract][Full Text] [Related]
7. Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer.
Mukherjee P; Madsen CS; Ginardi AR; Tinder TL; Jacobs F; Parker J; Agrawal B; Longenecker BM; Gendler SJ
J Immunother; 2003; 26(1):47-62. PubMed ID: 12514429
[TBL] [Abstract][Full Text] [Related]
8. Antigen choice determines vaccine-induced generation of immunogenic versus tolerogenic dendritic cells that are marked by differential expression of pancreatic enzymes.
Farkas AM; Marvel DM; Finn OJ
J Immunol; 2013 Apr; 190(7):3319-27. PubMed ID: 23420890
[TBL] [Abstract][Full Text] [Related]
9. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection.
Soares MM; Mehta V; Finn OJ
J Immunol; 2001 Jun; 166(11):6555-63. PubMed ID: 11359807
[TBL] [Abstract][Full Text] [Related]
10. Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model.
Rowse GJ; Tempero RM; VanLith ML; Hollingsworth MA; Gendler SJ
Cancer Res; 1998 Jan; 58(2):315-21. PubMed ID: 9443411
[TBL] [Abstract][Full Text] [Related]
11. Lack of effective MUC1 tumor antigen-specific immunity in MUC1-transgenic mice results from a Th/T regulatory cell imbalance that can be corrected by adoptive transfer of wild-type Th cells.
Turner MS; Cohen PA; Finn OJ
J Immunol; 2007 Mar; 178(5):2787-93. PubMed ID: 17312122
[TBL] [Abstract][Full Text] [Related]
12. Cellular and humoral immune responses to MUC1 mucin and tandem-repeat peptides in ovarian cancer patients and controls.
Snijdewint FG; von Mensdorff-Pouilly S; Karuntu-Wanamarta AH; Verstraeten AA; van Zanten-Przybysz I; Hummel P; Nijman HW; Kenemans P; Hilgers J
Cancer Immunol Immunother; 1999 Apr; 48(1):47-55. PubMed ID: 10235488
[TBL] [Abstract][Full Text] [Related]
13. Intradermal vaccination of MUC1 transgenic mice with MUC1/IL-18 plasmid DNA suppresses experimental pulmonary metastases.
Shi FF; Gunn GR; Snyder LA; Goletz TJ
Vaccine; 2007 Apr; 25(17):3338-46. PubMed ID: 17292519
[TBL] [Abstract][Full Text] [Related]
14. Tecemotide: an antigen-specific cancer immunotherapy.
Wurz GT; Kao CJ; Wolf M; DeGregorio MW
Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
[TBL] [Abstract][Full Text] [Related]
15. The Tat-conjugated N-terminal region of mucin antigen 1 (MUC1) induces protective immunity against MUC1-expressing tumours.
Yang H; Cho NH; Seong SY
Clin Exp Immunol; 2009 Nov; 158(2):174-85. PubMed ID: 19737144
[TBL] [Abstract][Full Text] [Related]
16. ICOSL-augmented adenoviral-based vaccination induces a bipolar Th17/Th1 T cell response against unglycosylated MUC1 antigen.
Carrell RK; Stanton RA; Ethier SP; LaRue AC; Soloff AC
Vaccine; 2018 Oct; 36(42):6262-6269. PubMed ID: 30219366
[TBL] [Abstract][Full Text] [Related]
17. CD4+ lymphocytes provide MUC1-specific tumor immunity in vivo that is undetectable in vitro and is absent in MUC1 transgenic mice.
Tempero RM; VanLith ML; Morikane K; Rowse GJ; Gendler SJ; Hollingsworth MA
J Immunol; 1998 Nov; 161(10):5500-6. PubMed ID: 9820526
[TBL] [Abstract][Full Text] [Related]
18. A novel chimeric DNA vaccine: enhancement of preventive and therapeutic efficacy of DNA vaccine by fusion of Mucin 1 to a heat shock protein 70 gene.
Choi DH; Woo JK; Choi Y; Seo HS; Kim CW
Mol Med Rep; 2011; 4(5):885-90. PubMed ID: 21725596
[TBL] [Abstract][Full Text] [Related]
19. Antibodies reactive with the protein core of MUC1 mucin are present in ovarian cancer patients and healthy women.
Richards ER; Devine PL; Quin RJ; Fontenot JD; Ward BG; McGuckin MA
Cancer Immunol Immunother; 1998 Jul; 46(5):245-52. PubMed ID: 9690452
[TBL] [Abstract][Full Text] [Related]
20. A MUC1/IL-18 DNA vaccine induces anti-tumor immunity and increased survival in MUC1 transgenic mice.
Snyder LA; Goletz TJ; Gunn GR; Shi FF; Harris MC; Cochlin K; McCauley C; McCarthy SG; Branigan PJ; Knight DM
Vaccine; 2006 Apr; 24(16):3340-52. PubMed ID: 16472547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
